Why the study?
Does induced acid or alkaline urine alter the pharmacokinetics of doxorubicin in females with advanced mammary carcinoma?
Does induced acid or alkaline urine alter the pharmacokinetics of doxorubicin in females with advanced mammary carcinoma?
Moderate acid/base metabolic disturbances do not alter the pharmacokinetics of doxorubicin up to 48 hours after infusion.
No routine urine pH adjustment needed for doxorubicin pharmacokinetics; leaves open effects on efficacy or toxicity in larger trials.
The common side effects of doxorubicin (DOX) treatment, i.e. vomiting and diarrhoea, would be expected to alter the pharmacokinetics of DOX in man, the efficacy of treatment, and further aggravate the side effects through acid/base disturbances. The pharmacokinetics were therefore investigated in 4 anthracycline naive females with advanced mammary carcinoma in 2 series of DOX monotherapy 70 mg/m2 administered with an interval of 4 weeks between the treatments. Sequential loading either with acid or base was instituted 2 days before and continued for 2 days after DOX infusion. Median urine pH was 5.0 or 8.0, and median arterial blood pH 7.30 or 7.43 respectively. Plasma and urine samples were analyzed by high performance liquid chromatography (HPLC). No difference was seen between the acid and alkaline condition for DOX or doxorubicinol with regard to clearance from blood plasma, area under the curve, renal clearance, renal drug clearance/renal creatinine clearance. Thus moderate acid/base metabolic disturbances did not alter the pharmacokinetics of DOX up to 48 h after DOX infusion.
No takes yet. Share an insight, caveat, or question.
Krarup‐Hansen et al. (1988) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: